Innovate Biopharma

Innovate Biopharma was a clinical-stage biotechnology company dedicated to developing novel medicines for autoimmune and inflammatory diseases, with a specialized focus on gastrointestinal disorders. The company's lead asset, larazotide acetate (INN-202), was a first-in-class tight junction regulator that reached Phase 3 clinical trials for the treatment of celiac disease. In early 2020, Innovate Biopharma completed a strategic merger with RDD Pharma to form 9 Meters Biopharma, a move intended to consolidate their gastrointestinal pipelines. Before the merger, the company was also advancing programs for ulcerative colitis and nonalcoholic steatohepatitis (NASH).